Orchestra BioMed Holdings (OBIO) EBITDA (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly EBITDA of -$22.1 million for Q1 2026, down 16.67% year-over-year from -$26.5 million in Q1 2025, and down 426.86% quarter-over-quarter from $6.8 million in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) EBITDA (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported EBITDA for 6 consecutive years, with -$22.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 16.67% year-over-year to -$22.1 million; the TTM figure through Mar 2026 stood at -$55.0 million (up 20.11% YoY), while the FY2025 annual figure was -$51.8 million, up 19.43% from the prior year.
- EBITDA fell to -$22.1 million in Q1 2026 per OBIO's latest filing, from $6.8 million in the prior quarter.
- Across five years, EBITDA topped out at $6.8 million in Q4 2025 and bottomed at -$22.1 million in Q1 2026.
- Historically, EBITDA has averaged -$13.1 million across 5 years, with a median of -$14.4 million in 2024.
- Annual changes were most pronounced in 2022 — EBITDA sank 10577.39% — and 2025, when it jumped 140.5%.
- Orchestra BioMed Holdings' EBITDA stood at -$9.8 million in 2022, then dropped by 26.99% to -$12.5 million in 2023, then tumbled by 33.62% to -$16.7 million in 2024, then surged by 140.5% to $6.8 million in 2025, then slumped by 426.86% to -$22.1 million in 2026.
- Business Quant data shows OBIO's EBITDA at -$22.1 million in Q1 2026, $6.8 million in Q4 2025, and -$20.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | -22.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.36 Mn |
| Mar 31, 2026 | -22.08 Mn |
| Dec 31, 2025 | 6.75 Mn |
| Sep 30, 2025 | -20.23 Mn |
| Jun 30, 2025 | -19.25 Mn |
| Mar 31, 2025 | -18.84 Mn |
| Dec 31, 2024 | -16.59 Mn |
| Sep 30, 2024 | -16.27 Mn |
| Jun 30, 2024 | -16.79 Mn |
| Mar 31, 2024 | -14.35 Mn |
| Dec 31, 2023 | -12.48 Mn |
| Sep 30, 2023 | -14.52 Mn |
| Jun 30, 2023 | -12.96 Mn |
| Mar 31, 2023 | -11.55 Mn |
| Dec 31, 2022 | -9.83 Mn |
| Sep 30, 2022 | -10.07 Mn |
| Jun 30, 2022 | -7.63 Mn |
| Mar 31, 2022 | -5.13 Mn |
| Dec 31, 2021 | -92,045.00 |
| Sep 30, 2021 | -94,445.00 |